Medical Licensing (MD/DO) · Independent exam preparation
ABD APPLIED Exam: Clinical Decisions and Practice Guide Study Guide
Practise diagnostic reasoning, treatment selection, biopsy decisions, pediatric risk assessment, and clinicopathologic interpretation for the ABD APPLIED Exam.
By CertMedbry · Updated 19 October 2026
Build decisions from discriminating findings: select useful tests, recognize emergencies, choose appropriate treatment, and connect pathology with clinical management. This guide addresses the American Board of Dermatology APPLIED Exam for initial general dermatology certification. Its 60 selected concepts follow the published approximate domain weights. The official APPLIED skills overview defines the full scope; this selective guide provides focused practice within that broader scope.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and certification pathway does this guide address?
This guide addresses the ABD APPLIED Exam in the staged pathway to initial general dermatology certification. Eligibility requires completed residency training and passage of all four CORE modules. BASIC assesses first-year resident fundamentals, while CORE assesses more advanced knowledge. The awarding-body name American Board of Dermatology is not itself an examination title.
How many questions are there, and how many are scored or pretest questions?
ABD states that APPLIED contains 200 multiple-choice questions, arranged into four sections of 50. The official page does not identify a scored-versus-pretest split, so no separate counts are established here.
What duration, breaks, and delivery setting are verified?
ABD describes an 8-hour examination offered at Pearson Test Centers. Each of the four sections lasts 94 minutes. Scheduled breaks are 20 minutes after section one, 60 minutes after section two, and 20 minutes after section three. These details were documented from the official ABD page on October 18, 2026; no publication or effective date is stated.
Which item styles and adaptive features are established?
All questions follow a multiple-choice format. Some include clinical images or photomicrographs, and virtual dermatopathology scans are excluded. The official page describes four timed sections with subjects mixed across the examination; it does not establish an adaptive testing algorithm. The practice questions here are independent, written, four-option learning drills.
What are the official domain weights?
The approximate weights are Medical Dermatology 55%, Pediatric Dermatology 15%, Surgical Dermatology 15%, and Dermatopathology 15%. This guide allocates its 60 concepts as 33, 9, 9, and 9, respectively. Both the 20 questions and the 20 flashcards use an 11, 3, 3, and 3 allocation.
Which outline dates apply, and how should the supporting CORE guide be used?
The current official pages documented on October 18, 2026 link an APPLIED overview internally marked Draft Updated: April 3, 2019. Its 2021 filename does not establish a 2021 revision. The referenced CORE knowledge-base guide was internally prepared April 16, 2018 and is a nonexhaustive working draft. No newer blueprint effective date is established. The APPLIED overview supplies the full skills scope; condition-specific references support clinical teaching.
APPLIED Exam Content Overview · APPLIED Examination Overview · ABD Certification Pathway CORE Exam Study Guide
What can this selective guide establish about readiness?
It supports practice in diagnosis, testing, management, communication, and clinicopathologic reasoning. It does not cover every condition or reproduce image-based examination performance. Use the official skills overview to identify remaining preparation needs. Neither a passing score nor a pass prediction is established by these learning drills.
APPLIED assesses physicians’ application of general dermatology knowledge after residency. BASIC, CORE, continuing certification, and subspecialty examinations are separate assessments. ABD certification is specialty board certification within the United States ABMS system; it does not itself confer a medical license. These independently authored learning materials are not official ABD examination items.
Outline used: Current ABD APPLIED Exam webpages consulted on 2026-10-10; currently linked APPLIED Examination Overview internally marked Draft Updated: April 3, 2019, despite its 2021 filename. No newer effective date is stated on the consulted exam webpages. Workbook label American Board of Dermatology names the awarding body; it is mapped here to the evidenced post-residency APPLIED Exam for initial general dermatology certification. The assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Medical Dermatology55%
1.Why does adalimumab require tuberculosis evaluation before treatment?
Tumor necrosis factor contributes to immune containment of tuberculosis. Blocking TNF with adalimumab can permit latent infection to reactivate or allow new infection to progress. The U.S. prescribing information requires evaluation for active tuberculosis and testing for latent infection before treatment, with treatment of latent infection before adalimumab when indicated. A positive screening result requires clinical assessment rather than automatic classification as active disease. Symptoms and exposure history remain important even after a negative test.
Apply it
A patient with plaque psoriasis is considering adalimumab and reports prior household tuberculosis exposure. Obtain the indicated tuberculosis evaluation and assess for active disease before choosing the timing of immunosuppression or preventive treatment.
Common pitfall: Do not transfer recommendations for lower-risk biologic classes to a TNF inhibitor. A negative screening test also does not exclude active tuberculosis in a symptomatic patient.
2.How do tuberculosis screening recommendations differ across psoriasis biologic classes?
Tuberculosis risk should be considered by drug class and patient exposure rather than treating all biologics as interchangeable. The NPF and IPC announcement adopted in November 2025 states that routine latent tuberculosis testing is not required solely for psoriasis treatment with IL-17 or selective IL-23 inhibitors. Separate epidemiologic or clinical indications still justify testing. The supporting statement acknowledges differences from some product labeling, so the actual agent, applicable prescribing information, and patient circumstances must be distinguished.
Apply it
A patient receiving a selective IL-23 inhibitor asks whether annual tuberculosis testing is automatic. Review new exposures, symptoms, occupational requirements, and the agent’s applicable labeling before deciding whether testing has an independent indication.
Common pitfall: Selective IL-23 inhibition is not a synonym for every interleukin-targeted therapy. Avoid extending the statement to TNF inhibitors or ignoring separate exposure risks.
Consensus Reached Regarding Routine Testing for Latent Tuberculosis Infection in Patients with Psoriasis by the National Psoriasis Foundation and the International Psoriasis Council · Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors
3.Which joint symptoms in psoriasis warrant assessment for psoriatic arthritis?
Psoriatic arthritis is inflammatory musculoskeletal disease associated with psoriasis, and its burden may be disproportionate to visible skin involvement. Persistent joint pain with swelling, stiffness after rest, swollen digits, or heel pain should prompt directed assessment. Early recognition matters because treatment can limit progressive joint damage. Ask about function and symptom timing rather than relying on the patient to volunteer an arthritis diagnosis. Nail changes may strengthen suspicion but do not independently establish joint disease.
Apply it
A patient with limited scalp psoriasis reports morning finger stiffness and a persistently swollen toe. Explore inflammatory symptoms and arrange appropriate joint assessment rather than escalating topical scalp therapy as the entire management plan.
Common pitfall: Mild skin disease does not exclude important joint disease. Conversely, joint pain alone is not diagnostic; mechanical and other inflammatory causes remain possible.
4.Why should acne antibiotics be combined with benzoyl peroxide?
Antibiotic exposure can select resistant Cutibacterium acnes and other organisms. Benzoyl peroxide has antimicrobial activity without the same resistance mechanism, making it an important partner when topical or systemic antibiotics are used for acne. Combination treatment also addresses more than one disease pathway when a retinoid is included. The decision is therefore not simply whether inflammatory lesions merit an antibiotic, but whether the regimen controls acne while minimizing unnecessary antibiotic selection pressure.
Apply it
A patient uses topical clindamycin alone for inflammatory facial acne and requests a refill. Reassess the regimen and incorporate benzoyl peroxide rather than continuing indefinite antibiotic monotherapy without a broader acne plan.
Common pitfall: Adding another antibiotic does not solve antibiotic resistance. Benzoyl peroxide is the relevant antimicrobial partner, while retinoids address follicular plugging and maintenance.
5.When should isotretinoin enter the acne treatment discussion?
Isotretinoin is an important option for severe acne, acne causing scarring or substantial psychosocial burden, and disease that fails appropriate standard treatment. The decision incorporates existing damage and future risk rather than counting lesions alone. Its major teratogenic risk requires careful pregnancy prevention and compliance with applicable prescribing requirements. Counseling should explain expected benefits, adverse effects, and monitoring so that the patient can make an informed decision rather than viewing escalation as a treatment failure.
Apply it
A patient has recurrent deep nodules and new scars despite an adequate combination regimen. Discuss isotretinoin eligibility, reproductive safety requirements, and monitoring rather than repeatedly extending oral antibiotics while additional permanent scars develop.
Common pitfall: Do not reserve isotretinoin discussion until scarring is extensive. Equally, substantial safety obligations mean that choosing it requires more than documenting persistent pimples.
6.How do topical retinoids address comedonal acne and maintenance?
Comedones arise from abnormal follicular keratinization and obstruction. Topical retinoids help normalize this process, treating existing comedones and reducing formation of new lesions. Their role therefore extends beyond short-term suppression of inflammatory papules. Application across acne-prone areas is more consistent with prevention than isolated spot treatment. Irritation can undermine adherence, so explain gradual introduction and compatible skin care. Treatment selection must also account for pregnancy and other patient-specific limitations.
Apply it
A patient applies acne medication only to visible whiteheads and repeatedly develops new lesions nearby. Explain preventive treatment of the affected field and adjust the regimen’s frequency and skin care to improve tolerability.
Common pitfall: A topical antibiotic is not an equivalent substitute for treatment of follicular plugging. Early irritation also should not automatically be interpreted as an allergic reaction.
7.Why must close contacts be treated simultaneously for scabies?
Scabies spreads through close contact, and an infested person can transmit mites before symptoms become apparent. Treating only the symptomatic patient leaves a reservoir for reinfestation within the household or among other close contacts. CDC recommends treating household members and close contacts at the same time. The practical task includes identifying relevant contacts, coordinating treatment, and explaining that absence of itching does not reliably establish absence of infestation during the incubation period.
Apply it
An adult improves after scabies treatment but develops new lesions after sharing a bed with an untreated partner. Coordinate simultaneous treatment for the patient and relevant contacts rather than assuming the medication itself is ineffective.
Common pitfall: Waiting for every contact to itch defeats coordinated control. Recurrent exposure can resemble drug failure even when the initial treatment killed the patient’s mites.
8.Which environmental measures help prevent scabies reinfestation safely?
Environmental control complements treatment by addressing recently used clothing, towels, and bedding. CDC recommends hot washing and hot drying or dry cleaning, with items that cannot be cleaned sealed in a bag for several days to a week. Focus on items used close to the skin during the three days before treatment. Avoid insecticide sprays and fumigants: recommended laundering and temporary isolation of items address the environmental reservoir without unnecessary pesticide exposure. Environmental measures must accompany treatment of affected people and relevant contacts.
Apply it
A household begins coordinated scabies treatment tonight and proposes spraying mattresses with insecticide. Explain how to handle recently used bedding and clothing, including bagging unwashable items, and advise against pesticide spraying.
Common pitfall: Cleaning every household surface cannot compensate for an untreated close contact. More intensive chemical treatment does not necessarily provide safer or more effective control.
9.How does crusted scabies change treatment and infection control?
Crusted scabies involves a very high mite burden and can be highly contagious, including through contaminated materials. Thick scale may impede topical penetration, and itching may be less prominent than expected. CDC describes treatment using oral ivermectin together with a topical scabicide, with the schedule tailored to severity. Recognition should trigger coordinated infection-control measures and contact assessment. A routine single-agent approach for uncomplicated scabies is insufficient for this more difficult infestation.
Apply it
A nursing-facility resident has extensive hyperkeratotic plaques and multiple affected caregivers. Consider crusted scabies, initiate appropriate combined treatment planning, and coordinate facility infection control instead of treating each itchy caregiver as an unrelated case.
Common pitfall: Minimal itch does not make crusted scabies unlikely. Its heavy mite burden creates substantial transmission risk even when the patient’s subjective symptoms seem modest.
10.How should permethrin be applied for classic adult scabies?
For classic adult scabies, apply permethrin 5% cream to all skin from the neck down, rather than only to visible papules or burrows, and wash it off after 8–14 hours. Another application about one week later may be necessary to eliminate newly hatched mites. Explain complete coverage, including skin folds and spaces between fingers and toes. Coordinate contact treatment and environmental measures. Infants and young children can have head and neck involvement and require age-specific application instructions rather than automatic use of the adult neck-down approach.
Apply it
An adult reports new burrows after applying permethrin only between the fingers. Teach complete neck-down application, the 8–14-hour contact period, and possible repeat application about one week later; also review contact treatment and renewed exposure.
Common pitfall: Spot treatment misses mites outside visible lesions. Persistent itching alone does not establish ongoing infestation; new burrows and the treatment history are more informative.
11.Why does syphilis diagnosis require both treponemal and nontreponemal tests?
Treponemal and nontreponemal tests provide different information. Treponemal tests support exposure to Treponema pallidum but often remain reactive after treatment. Quantitative nontreponemal tests, such as RPR, help assess disease activity and response over time, although false-positive and false-negative results occur. Using only one test type can misclassify infection. Interpret both with the examination, exposure history, prior treatment documentation, and disease stage rather than treating any single laboratory result as self-explanatory.
Apply it
A patient with a palmoplantar eruption has a reactive RPR. Obtain the appropriate treponemal confirmation and evaluate the clinical stage and neurologic or ocular symptoms before selecting treatment and establishing a follow-up baseline.
Common pitfall: A reactive RPR alone does not establish syphilis, and a persistently positive treponemal test does not by itself prove treatment failure or reinfection.
12.What constitutes a clinically significant change in an RPR titer?
A fourfold change in a quantitative nontreponemal titer equals a change of two dilutions, such as 1:32 to 1:8 or 1:8 to 1:32. CDC uses this magnitude as a clinically significant difference when results are obtained with the same test method, preferably from the same laboratory. Smaller fluctuations can reflect variation rather than a meaningful biological change. Direction, timing, treatment history, symptoms, and new exposure determine whether the change suggests response or renewed concern.
Apply it
A patient’s RPR falls from 1:64 before therapy to 1:16 during follow-up. Recognize a fourfold decline, then assess whether the timing and clinical course fit the expected response for the patient’s stage.
Common pitfall: A decrease from 1:32 to 1:16 is twofold, not fourfold. Do not interchange RPR and VDRL titers as though their numerical values are equivalent.
13.How should discordant reverse-sequence syphilis tests be resolved?
A reactive initial treponemal immunoassay with a nonreactive RPR requires a second treponemal test using different antigens or methodology, preferably TP-PA. If that second test is positive, prior treatment and exposure history guide management. Documented adequately treated infection without reexposure generally does not require additional treatment. A previously untreated patient needs treatment based on the established stage. Recent exposure may justify repeat nontreponemal testing because early infection can precede RPR reactivity.
Apply it
A screening immunoassay is reactive, RPR is nonreactive, and TP-PA is reactive. Review documented prior therapy and recent sexual exposure before deciding between no additional treatment, repeat testing, or treatment of previously unrecognized infection.
Common pitfall: Do not label every discordant screen a false positive. Conversely, two positive treponemal tests do not establish that previously treated infection has become active again.
14.Which criteria support early latent syphilis classification?
Latent syphilis is seroreactivity without clinical evidence of primary, secondary, or tertiary disease. Early latent classification is supported when, during the preceding year, there was documented seroconversion; a sustained fourfold or greater nontreponemal titer increase persisting for more than two weeks in a previously treated person; unequivocal primary or secondary symptoms; or a partner with documented primary, secondary, or early latent syphilis. Early latent infection can also be assumed when the only possible exposure occurred within the preceding 12 months. Without qualifying evidence, classify infection as late latent or of unknown duration.
Apply it
An asymptomatic patient has positive serology and no prior tests. Establish whether symptoms, a documented partner diagnosis, or the complete exposure history confines acquisition to the preceding year before selecting an early latent treatment course.
Common pitfall: A high RPR titer, a newly discovered positive test, an unqualified partner history, or a brief titer fluctuation does not establish early latent infection.
15.Which findings distinguish alopecia areata from destructive hair loss?
Alopecia areata is an autoimmune, generally nonscarring form of hair loss in which follicles remain capable of producing hair. Smooth patches with preserved follicular openings favor this process over disorders that destroy follicles and leave scar. Short tapered hairs near an active patch can support the diagnosis. Examine the scalp, eyebrows, eyelashes, body hair, and nails, because the distribution may extend beyond a single patch and helps define the clinical pattern.
Apply it
A patient develops a round smooth scalp patch without scale or loss of follicular openings. Consider alopecia areata while examining the patch edge, nails, and remaining hair-bearing sites for supporting findings and broader involvement.
Common pitfall: Hair loss alone is not enough to diagnose alopecia areata. Scale, broken hairs, inflammation, or absent follicular openings should redirect the differential and testing.
16.How should alopecia areata extent shape counseling?
Alopecia areata ranges from discrete patches to complete scalp hair loss, termed alopecia totalis, or loss across the scalp and body, termed alopecia universalis. These patterns describe extent rather than a guaranteed sequence of progression. Its course can include regrowth and recurrence, and individual outcomes are difficult to predict. Counseling should explain preserved follicular potential while acknowledging uncertainty and the psychosocial effects of visible hair loss, which may be substantial even with limited surface involvement.
Apply it
A patient with two new patches asks whether complete body hair loss is inevitable. Explain the range of patterns and unpredictable course, document baseline extent, and discuss treatment and support without promising permanent regrowth.
Common pitfall: Nonscarring does not mean emotionally minor or reliably reversible on a fixed timetable. Avoid guaranteeing either progression to extensive disease or spontaneous complete recovery.
17.Why does patch testing require delayed readings?
Allergic contact dermatitis is a delayed immune response, so an immediate inspection cannot reliably detect the relevant reaction. Patch testing places selected allergens against the skin and uses later examinations to identify responses that develop over time. This differs from skin-prick testing for immediate allergy. Test selection should follow the distribution and exposure history, including occupational products and personal-care substances. A properly timed series of readings is part of the diagnostic procedure rather than optional follow-up.
Apply it
A hairdresser has recurrent hand dermatitis linked to workdays. Arrange appropriately selected patch testing with the required later readings instead of using a same-day skin-prick result to exclude allergy to workplace contactants.
Common pitfall: A negative immediate reading does not rule out delayed contact allergy. Antihistamine-responsive itching also does not establish which immune mechanism caused the dermatitis.
18.How does a positive patch test become an actionable diagnosis?
A positive patch test identifies sensitization, but the clinician must determine whether the allergen explains the patient’s current eruption. Establish exposure, anatomical plausibility, and the timing of symptoms. Then translate the result into specific avoidance instructions, including relevant ingredient names and sources of exposure. Continued contact can sustain dermatitis despite otherwise appropriate anti-inflammatory treatment. This connection between test result and real-world exposure is what turns laboratory information into useful patient care.
Apply it
Patch testing identifies an allergen present in a patient’s daily moisturizer. Link the ingredient to the exposure history and provide practical substitute guidance rather than handing over a result sheet without explaining what to stop.
Common pitfall: Not every positive reaction explains the current rash. Treating all positive tests as equally relevant can cause unnecessary restrictions while the actual exposure continues.
19.Which clinical pattern supports hidradenitis suppurativa?
Hidradenitis suppurativa is a chronic inflammatory disease centered on hair follicles, typically producing recurrent painful nodules or abscess-like lesions in intertriginous regions. Axillary, groin, inframammary, or buttock involvement, recurrence, scarring, and tunnels support the diagnosis. It is not simply repeated independent bacterial abscess formation. Recognizing the pattern allows discussion of long-term disease control, pain, drainage, and functional impairment rather than limiting each visit to treatment of the most recent swollen lesion.
Apply it
A patient reports years of painful groin and axillary nodules with drainage and scars. Ask about recurrence and examine for tunnels before labeling the current lesion another isolated boil requiring only short-term treatment.
Common pitfall: A positive bacterial culture does not erase the underlying inflammatory diagnosis. Recurrent characteristic lesions and structural changes require assessment beyond episodic treatment for presumed infection.
20.Why do tunnels change the management of hidradenitis suppurativa?
Tunnels represent persistent structural disease beneath the skin rather than a transient superficial papule. They can repeatedly drain and remain problematic even when medication reduces surrounding inflammation. Management must therefore distinguish active inflammatory lesions from established tunnels and scarring, because procedural treatment may be needed alongside medical therapy. Assess the distribution, pain, drainage, and effect on movement or daily activities. A plan that targets inflammation alone may leave an important source of continuing symptoms untreated.
Apply it
A patient’s inflammatory nodules improve with treatment, but one axillary tract continues to drain from the same openings. Reassess the persistent tunnel for procedural management instead of assuming every drainage episode requires a new antibiotic.
Common pitfall: Reduced redness does not mean all disease has resolved. Conversely, established scarring is not a reliable measure of current inflammatory activity or medication response.
Hidradenitis Suppurativa · Hidradenitis Suppurativa (HS): Diagnosis, Treatment, and Steps to Take
21.How should hidradenitis suppurativa education address causes and self-care?
Hidradenitis suppurativa is not caused by poor hygiene and is not contagious. Clear explanation can reduce shame and improve participation in long-term treatment. Individualized care may address friction, comfortable clothing, wound care, smoking cessation, and weight-related considerations without treating these factors as moral failings or guaranteed cures. Ask about pain, odor, drainage, work, and intimacy. These consequences affect whether a medically reasonable treatment plan is practical and whether additional support is needed.
Apply it
A patient avoids follow-up because family members blame the disease on uncleanliness. Explain its inflammatory nature, address wound-care needs and modifiable aggravators, and ask which daily effects most interfere with treatment participation.
Common pitfall: Advice to wash more is neither an explanation nor adequate therapy. Lifestyle measures should support disease management without replacing indicated medical or procedural treatment.
22.Which findings demand emergency assessment for SJS or TEN?
Stevens–Johnson syndrome and toxic epidermal necrolysis are severe reactions characterized by painful skin, epidermal injury or detachment, and prominent mucosal involvement, often after a medication exposure. Systemic illness and rapidly evolving erosions distinguish this emergency from many uncomplicated drug eruptions. Management requires immediate withdrawal of suspected culprit drugs and urgent hospital assessment for supportive care and specialist involvement. The presence of limited visible detachment early in the course should not delay escalation when the clinical pattern is concerning.
Apply it
A patient recently started a medication and now has fever, skin pain, oral erosions, and dusky lesions. Arrange emergency assessment and stop the suspected culprit rather than scheduling routine review after trying an antihistamine.
Common pitfall: Do not wait for extensive peeling before acting. An early severe reaction can have little detachment, while pain and mucosal injury already indicate substantial concern.
23.How do typical erythema multiforme lesions differ from SJS or TEN?
Erythema multiforme typically produces raised target lesions with concentric zones and often begins on acral sites. It is frequently associated with infection, particularly herpes simplex. SJS and TEN more often feature widespread painful dusky or atypical flat lesions, prominent mucosal erosions, and epidermal detachment in a medication-related setting. These are distinct clinical entities rather than interchangeable labels. Morphology, distribution, systemic illness, mucosal severity, and drug timing should be interpreted together.
Apply it
One patient has recurrent concentric targets on the hands after cold sores; another has painful truncal duskiness and extensive mucosal erosions after a new drug. Use the complete patterns to distinguish likely erythema multiforme from SJS/TEN.
Common pitfall: The word target alone is insufficient. Atypical flat lesions in a systemically ill patient should not be reassured away as uncomplicated erythema multiforme.
24.How does the lifetime of an individual wheal guide the urticaria differential?
An ordinary urticarial wheal usually resolves within 24 hours, even though new lesions may continue elsewhere. Ask how long one marked lesion remains rather than how many days the overall eruption has lasted. Lesions that remain fixed, are painful, or leave bruising deserve reconsideration of the diagnosis, including possible urticarial vasculitis. Photographs or marking a lesion can clarify uncertain histories. The time course of individual lesions is often more discriminating than their appearance during one visit.
Apply it
A patient says hives have lasted two weeks. Ask whether each wheal disappears within a day or remains in exactly the same place; fixed bruising lesions would prompt a different evaluation from migrating itchy wheals.
Common pitfall: Two weeks of recurrent wheals does not mean each lesion lasted two weeks. Overall disease duration and individual lesion duration answer different diagnostic questions.
25.When does recurrent urticaria become chronic, and how should testing be directed?
Urticaria recurring for more than six weeks is chronic. When no specific reproducible trigger explains it, chronic spontaneous urticaria is a useful clinical category. Evaluation starts with history, examination, medication review, and any clues to inducible disease or systemic illness. Broad allergy panels often fail to explain daily spontaneous wheals and may produce incidental results. Testing should answer a focused clinical question rather than assuming every chronic eruption is caused by an undiscovered food allergy.
Apply it
An adult has daily transient wheals for three months without a consistent relationship to meals. Review medications, physical triggers, and systemic symptoms before ordering broad food testing or prescribing an extensive elimination diet.
Common pitfall: A positive sensitization test does not prove that a food causes chronic wheals. Reproducible clinical exposure patterns matter more than an isolated laboratory result.
Hives: Diagnosis and treatment · Key messages: Urticaria guidelines
26.Why are nonsedating antihistamines central to chronic urticaria treatment?
Histamine contributes to the itch and wheal formation of urticaria, so second-generation H1 antihistamines are a central initial treatment. Persistent disease may require clinician-guided adjustment or additional therapy such as omalizumab. The treatment plan should consider regular symptom control and functional effects rather than repeated rescue treatment alone. Long-term systemic corticosteroids have substantial adverse effects and are not a suitable routine maintenance strategy for chronic spontaneous urticaria.
Apply it
A patient with chronic spontaneous urticaria repeatedly receives short steroid courses but has no sustained controller plan. Review regular second-generation antihistamine use and an appropriate escalation pathway instead of relying on recurring systemic corticosteroid exposure.
Common pitfall: Temporary steroid improvement does not establish a safe long-term strategy. Sedation and daily functioning also matter when selecting antihistamines for persistent symptoms.
Hives: Diagnosis and treatment · Key messages: Urticaria guidelines
27.Which clinical features help distinguish rosacea from acne?
Rosacea commonly affects the central face with persistent redness, flushing, visible vessels, or inflammatory papules and pustules. Comedones favor acne rather than rosacea, although conditions can coexist. Burning, stinging, sensitivity, and ocular symptoms can provide additional clues. Treatment should match the manifestations actually present: reducing inflammatory lesions is a different goal from managing persistent erythema or ocular disease. A single generic acne regimen may therefore miss important components of the patient’s condition.
Apply it
An adult has central facial papules, flushing, and burning but no comedones. Ask about eye symptoms and triggers, then select rosacea-directed treatment rather than assuming that every pustular facial eruption is acne.
Common pitfall: Papules and pustules alone do not establish acne. Conversely, redness alone does not prove rosacea; distribution, symptoms, exposures, and competing diagnoses remain relevant.
Rosacea Symptoms, Causes, & Risk Factors | NIAMS · Rosacea: Diagnosis, Treatment, and Steps to Take
28.When do ocular symptoms in rosacea require urgent assessment?
Ocular rosacea can cause dryness, irritation, eyelid inflammation, and a gritty sensation, but painful ocular inflammation or blurred vision raises concern for more consequential eye involvement. Skin severity does not reliably indicate ocular severity. Ask directly about eye pain, photophobia, and vision change rather than restricting the assessment to facial lesions. Concerning symptoms warrant prompt eye assessment because corneal involvement can threaten vision and should not be managed as a cosmetic extension of facial redness.
Apply it
A patient with mild facial rosacea reports a painful red eye and new blurred vision. Arrange urgent ophthalmic assessment rather than simply increasing topical facial treatment or assuming the symptoms are ordinary dry eye.
Common pitfall: Mild cutaneous disease does not make visual symptoms low risk. Routine eyelid hygiene advice is insufficient when pain or impaired vision suggests corneal involvement.
29.How does pemphigus produce fragile blisters and mucosal erosions?
Pemphigus is an autoimmune disease in which antibodies interfere with proteins that maintain adhesion between epidermal cells, particularly desmogleins. Loss of adhesion makes the epithelium fragile, producing blisters that may rupture into painful erosions. Oral involvement is especially important in pemphigus vulgaris and can precede recognized skin disease. Persistent mucosal erosions with fragile cutaneous blisters should prompt tissue and antibody evaluation rather than repeated treatment for presumed superficial infection alone.
Apply it
A patient has months of painful oral erosions followed by easily ruptured skin blisters. Consider pemphigus and arrange appropriate diagnostic evaluation instead of treating each erosion as an unrelated episode of candidiasis or trauma.
Common pitfall: The absence of intact blisters does not exclude a blistering disease. Fragile pemphigus blisters may already have ruptured by the time of examination.
Pemphigus · Pemphigus: Diagnosis, Treatment, and Steps to Take
30.Why must pemphigus management monitor both disease activity and treatment harm?
Pemphigus treatment suppresses the autoimmune process while supporting healing of damaged skin and mucosa. Corticosteroids, other immunosuppressive agents, and targeted treatments can control disease but introduce infection and other treatment-related risks. Follow-up should distinguish new blister formation from slow healing, secondary infection, or medication toxicity. Oral pain, nutrition, hydration, and wound care also influence outcomes. A lower visible lesion count alone does not establish that the overall treatment plan is safe or sufficient.
Apply it
A treated patient develops fewer new blisters but increasing focal wound pain and fever. Evaluate for infection and treatment complications rather than automatically increasing immunosuppression because the patient reports that the skin feels worse.
Common pitfall: Symptoms during therapy are not always autoimmune relapse. Escalating immunosuppression without evaluating infection can worsen a complication that requires a different response.
31.How should rosacea trigger advice be individualized?
Heat, sun exposure, emotional stress, alcohol, or particular foods can aggravate rosacea in some patients, but triggers vary. Ask the patient to identify reproducible associations rather than imposing universal restrictions. Gentle skin care and sun protection support management while treatment addresses specific manifestations. A symptom diary can connect exposures with flares and guide practical changes. Trigger avoidance complements medication; it does not imply that persistent disease results from inadequate effort or that every flare has one identifiable cause.
Apply it
A patient reports flares after hot outdoor exercise but no relationship to spicy food. Prioritize cooling strategies and sun protection while continuing appropriate therapy rather than requiring dietary restrictions that have no demonstrated personal relevance.
Common pitfall: A standard list of possible triggers is not proof that every item affects this patient. Excessive restrictions can reduce quality of life without improving disease.
32.How do absolute and relative treatment effects change evidence appraisal?
Relative effects describe proportional change, whereas absolute effects show how many additional patients experience an outcome. If an adverse outcome falls from 20% to 10%, the relative reduction is 50%, but the absolute reduction is 10 percentage points. The number needed to treat is the reciprocal of the absolute reduction expressed as a proportion: 1 divided by 0.10 equals 10. Interpret the outcome and follow-up interval alongside these calculations before deciding whether the effect is clinically useful.
Apply it
A hypothetical dermatology trial reports flares in 30% of controls and 20% of treated participants over six months. Calculate a 10-percentage-point absolute reduction and a six-month number needed to treat of 10.
Common pitfall: A large relative reduction can accompany a small absolute benefit. Do not calculate number needed to treat using percentages as whole numbers or omit the follow-up interval.
Chapter 6: Choosing effect measures and computing estimates of effect | Cochrane
33.How do neurologic or ocular findings alter syphilis evaluation and treatment?
Patients with ocular symptoms and reactive syphilis serology need a full ocular examination, including cranial nerve assessment. Neurologic involvement or cranial nerve dysfunction warrants cerebrospinal fluid evaluation. Isolated ocular disease confirmed on examination, without neurologic abnormalities, does not require CSF examination before treatment. Treat ocular syphilis using the neurosyphilis regimen even if CSF findings are normal: adult aqueous crystalline penicillin G 18–24 million units intravenously per day, given as 3–4 million units every four hours or by continuous infusion, for 10–14 days.
Apply it
A patient with secondary syphilis has examination-confirmed uveitis and a normal neurologic and cranial nerve examination. Arrange ophthalmology collaboration and intravenous penicillin treatment without delaying therapy for a routine lumbar puncture.
Common pitfall: Normal CSF does not exclude ocular syphilis. Stage-based intramuscular benzathine penicillin alone does not replace the recommended ocular or neurosyphilis treatment regimen.
Pediatric Dermatology15%
34.Which infantile hemangiomas need early specialist evaluation?
Infantile hemangioma risk depends on location, size, pattern, and complications rather than benign histology alone. Lesions near the eye, airway-associated distributions, ulcerated lesions, and lesions threatening function or permanent disfigurement warrant early assessment. Segmental patterns can also signal associated structural abnormalities. The AAP guideline emphasizes recognizing high-risk lesions promptly because growth during early infancy can create harm before a routine later review. Referral decisions should anticipate consequences rather than wait for established disability.
Apply it
A young infant has a rapidly enlarging upper-eyelid hemangioma beginning to narrow the visual opening. Arrange prompt specialist evaluation because waiting for spontaneous involution could allow visual impairment during an important developmental period.
Common pitfall: Benign does not mean harmless. A small lesion in a functionally critical location may require faster assessment than a larger uncomplicated lesion on the trunk.
Clinical Practice Guideline for the Management of Infantile Hemangiomas
35.How does childhood scabies differ from the classic adult distribution?
Infants and young children can have scabies involving the scalp, face, and neck as well as other body sites. A neck-down adult treatment instruction can therefore leave involved areas untreated. CDC advises application to the head, neck, and body in children using a clinician-recommended product and age-specific instructions. Permethrin 5% is approved for patients at least two months old. Oral ivermectin safety has not been established in children weighing less than 15 kg, so adult treatment choices cannot simply be scaled down.
Apply it
An infant with household scabies has lesions on the scalp and neck. Review age-appropriate treatment and coverage with the caregivers rather than copying the adult household member’s neck-down instructions.
Common pitfall: Head involvement does not exclude scabies in a young child. Product selection and application instructions must both account for age.
36.When do multiple cutaneous hemangiomas justify hepatic screening?
The AAP guideline recommends screening infants with five or more cutaneous infantile hemangiomas for hepatic involvement using ultrasonography. The skin lesion count acts as a practical risk marker rather than evidence that liver disease is already present. Hepatic hemangiomas can have systemic consequences, including high-output cardiac failure and, with substantial disease, consumptive hypothyroidism. Recognition therefore changes the evaluation from documenting skin lesions alone to considering clinically important internal disease and its complications.
Apply it
An otherwise well infant has six separate cutaneous infantile hemangiomas. Arrange hepatic ultrasonography under the guideline’s screening recommendation, even though feeding and examination currently reveal no obvious cardiac or abdominal abnormality.
Common pitfall: A normal abdominal examination does not replace recommended screening. Conversely, a single uncomplicated cutaneous lesion does not automatically require a search for hepatic hemangiomas.
Clinical Practice Guideline for the Management of Infantile Hemangiomas
37.Why is oral propranolol the usual first systemic treatment for infantile hemangioma?
For an infantile hemangioma requiring systemic therapy, the AAP guideline recommends oral propranolol as first-line treatment unless contraindications or other circumstances prevent its use. Systemic therapy is appropriate when the lesion’s risk exceeds what observation or a limited topical approach can address. Before treatment, assess relevant cardiovascular and respiratory history and establish appropriate monitoring. Counseling must include feeding-related hypoglycemia precautions, including administration with or after feeds and withholding treatment during poor intake or significant illness.
Apply it
An infant has a function-threatening hemangioma requiring systemic treatment. After appropriate pretreatment assessment, plan oral propranolol and teach caregivers how feeding interruptions and illness alter administration, rather than providing medication instructions without a safety plan.
Common pitfall: A topical beta-blocker is not interchangeable with systemic treatment for a bulky high-risk lesion. Propranolol also requires specific precautions when an infant is not feeding normally.
Clinical Practice Guideline for the Management of Infantile Hemangiomas
38.When should localized childhood eczema prompt consideration of contact allergy?
Repeated eczema in the same exposure distribution should prompt a directed contact history rather than automatic attribution to atopic dermatitis. Ask about skin-care products, topical medications, adhesives, jewelry, and activities that contact the affected area. Allergic contact dermatitis is delayed, so patch testing with later readings is the relevant allergy investigation when the history supports it. Interpret any positive result against actual exposure and distribution. Atopic dermatitis and contact allergy can coexist; one diagnosis does not exclude the other.
Apply it
A child’s generalized eczema improves, but dermatitis repeatedly returns beneath an adhesive dressing. Review the dressing and topical products and consider directed patch testing instead of simply increasing treatment over an ongoing exposure.
Common pitfall: A recurrent exposure-shaped eruption is not explained by the label sensitive skin. A positive patch test still requires clinical relevance before recommending avoidance.
Patch testing can find what's causing your rash · Eczema types: Atopic dermatitis diagnosis and treatment
39.Why does tinea capitis require oral antifungal treatment?
Tinea capitis involves scalp hair and follicles, which topical creams do not adequately treat. CDC therefore describes prescription oral antifungal therapy as necessary for scalp ringworm. Scale, patchy hair loss, and broken hairs support suspicion, although inflammatory presentations can be mistaken for bacterial disease. Diagnostic evaluation and treatment selection should consider the clinical pattern and likely organism. Adjunctive shampoo may reduce transmission but does not replace systemic therapy for infection within the hair-bearing structures.
Apply it
A school-age child has a scaly alopecic scalp patch with broken hairs. Evaluate for tinea capitis and select appropriate oral treatment rather than prescribing only the topical antifungal used for a sibling’s body ringworm.
Common pitfall: The word ringworm does not imply identical treatment at every site. Scalp involvement requires a different route from many uncomplicated infections of glabrous skin.
40.Why should corticosteroid creams be avoided on suspected ringworm?
Corticosteroids can suppress the visible inflammation of a dermatophyte infection without eliminating the fungus. The eruption may temporarily look less red while infection extends or becomes less recognizable. CDC advises against steroid creams for ringworm or an undiagnosed rash that could be ringworm. When a lesion has an annular or spreading scaly pattern, establish the diagnosis and use appropriate antifungal treatment rather than interpreting short-term symptom suppression as proof of an inflammatory eczema diagnosis.
Apply it
A child’s annular trunk rash becomes less itchy but spreads after a steroid-containing cream. Reconsider dermatophyte infection and obtain appropriate evaluation instead of increasing steroid potency because the original inflammation has not fully cleared.
Common pitfall: Improvement in redness is not proof that the cause has been treated. Steroid-antifungal combination products can obscure whether the antifungal regimen is appropriate or sufficient.
41.How does barrier care support treatment of childhood atopic dermatitis?
Atopic dermatitis combines inflammation with impaired skin-barrier function, allowing dryness and irritation to sustain itch and scratching. Regular moisturization and individualized gentle skin care support the barrier, while indicated anti-inflammatory therapy treats active eczema. These components work together rather than competing as alternative explanations of disease. Plans should specify practical application and address tolerability, bathing habits, and family routines. Persistent uncontrolled disease warrants reassessment rather than assuming that more moisturizer alone will suppress substantial inflammation.
Apply it
A child’s eczema improves during prescribed anti-inflammatory treatment but repeatedly flares when all skin care stops. Build an understandable maintenance plan with regular moisturization and clear instructions for managing new inflammatory areas.
Common pitfall: Moisturizer is foundational but does not replace treatment of an active inflammatory flare. Conversely, prescribing medication without workable barrier care can leave avoidable dryness and irritation.
42.When are antibiotics inappropriate for childhood eczema?
Atopic skin is frequently colonized with bacteria, but colonization is not equivalent to a clinical infection that benefits from antibiotics. The AAD Choosing Wisely recommendations discourage oral antibiotics for atopic dermatitis without evidence of infection. Assess for findings such as new purulence, spreading erythema, tenderness, or systemic illness in context. When the presentation is an uncomplicated inflammatory flare, improving eczema control and barrier care is more appropriate than exposing the child to unnecessary antimicrobial treatment.
Apply it
A child has dry itchy flexural plaques without purulence, spreading warmth, fever, or new pain. Treat the eczema flare and review skin care rather than prescribing an oral antibiotic solely because atopic skin can carry bacteria.
Common pitfall: A positive surface culture alone may reflect colonization. Antibiotics do not substitute for anti-inflammatory treatment and can add adverse effects and resistance without helping uninfected eczema.
Choosing wisely: Recommendations about treatments, tests, and procedures
Surgical Dermatology15%
43.How should dermoscopy and biopsy work together in suspected melanoma?
Dermoscopy supplements the clinical examination by revealing structures and their distribution within a pigmented lesion. In trained hands, it improves diagnostic assessment; asymmetric structures or colors and an atypical pigment network increase concern when interpreted with the whole lesion and history. It does not establish Breslow thickness or replace biopsy of a suspicious lesion. When complete sampling is feasible, use a narrow clinical margin and sufficient depth to avoid transection. Complete deep saucerization can be appropriate; adequacy depends on completeness and depth.
Apply it
A small changing lesion has asymmetric pigmentation on clinical and dermoscopic assessment. Perform complete, adequately deep narrow-margin diagnostic sampling rather than using dermoscopy as a reason to postpone tissue diagnosis.
Common pitfall: Neither a reassuring isolated dermoscopic feature nor the name of a biopsy technique establishes adequacy. A superficial transecting shave may prevent reliable staging.
Guidelines of care for the management of primary cutaneous melanoma · APPLIED Examination Overview
44.When is partial sampling reasonable for a suspected melanoma?
Complete narrow-margin biopsy is preferred for suspected melanoma, but selected very large lesions or lesions at anatomically difficult sites may require partial sampling. The AAD guideline permits this when complete initial removal is impractical. Choose a representative area, particularly the most clinically concerning component, and communicate the limitation to the pathologist. Partial sampling can miss invasion or underestimate maximum thickness, so pathology must be reconciled with the remaining lesion and the broader clinical impression.
Apply it
A broad irregular facial patch cannot reasonably be removed entirely at the first visit. Select representative diagnostic tissue from the most concerning area and plan further assessment if the limited pathology does not explain the lesion.
Common pitfall: A benign or in-situ finding in a small sample does not prove the entire lesion lacks invasion. Sampling limitations remain relevant after the report arrives.
Guidelines of care for the management of primary cutaneous melanoma
45.How does melanoma thickness determine definitive excision margins?
For invasive melanoma, the AAD guideline generally recommends a 1-cm clinical excision margin for Breslow thickness up to 1.0 mm, 1–2 cm for thickness greater than 1.0 through 2.0 mm, and 2 cm for thickness greater than 2.0 mm. These are definitive treatment margins, distinct from the narrow margin used for diagnostic biopsy. Anatomy, function, reconstruction, and patient circumstances influence planning, particularly when choosing within the 1–2-cm range. Difficult anatomy requires an explicit specialist plan rather than assuming a smaller visible lesion needs a smaller margin.
Apply it
A completely sampled 1.5-mm invasive melanoma requires discussion of a 1–2-cm clinical margin. Explain how the location and functional consequences inform selection within that range, while preserving adequate oncologic treatment.
Common pitfall: Surface diameter does not determine the definitive margin. A transected biopsy base may underestimate thickness and leave the appropriate margin uncertain.
Guidelines of care for the management of primary cutaneous melanoma · Melanoma Treatment (PDQ®) — Health Professional Version
46.What is the purpose of sentinel lymph node biopsy in melanoma?
Sentinel lymph node biopsy assesses microscopic spread to the first regional draining nodes for pathological staging and prognosis in clinically node-negative patients. Generally, do not perform it routinely for melanoma in situ or uncomplicated T1a melanoma, defined as less than 0.8 mm thick without ulceration. Discuss and consider it for T1b disease: less than 0.8 mm with ulceration, or 0.8–1.0 mm with or without ulceration. Discuss and offer it to appropriate clinically node-negative patients with tumors thicker than 1.0 mm. Selected T1a cases may merit consideration when adverse features such as young age, lymphovascular invasion, or a high mitotic rate increase estimated nodal risk, particularly in combination. A positive deep biopsy margin near the 0.8-mm boundary can also justify discussion because true thickness remains uncertain. Balance staging value against procedural risks, comorbidities, and patient preferences.
Apply it
For clinically node-negative patients, a completely sampled 0.6-mm nonulcerated melanoma without adverse features generally needs no routine sentinel node biopsy; a 0.9-mm melanoma warrants discussion and consideration; and a 1.5-mm melanoma warrants discussion and an offer when the patient is an appropriate candidate. A 0.7-mm nonulcerated tumor with lymphovascular invasion warrants individualized consideration despite its T1a category. Explain that nodal staging accompanies rather than replaces definitive skin excision.
Common pitfall: Sentinel node biopsy does not replace primary excision, and a clinically suspicious enlarged node requires directed evaluation rather than routine sentinel-node staging. Avoid treating T1a exceptions as an indication for every thin melanoma.
Guidelines of care for the management of primary cutaneous melanoma · Melanoma Treatment (PDQ®) — Health Professional Version
47.When can staged excision help manage melanoma in situ?
Melanoma in situ is confined to the epidermis, but its peripheral extent may be difficult to define clinically, especially in lentigo maligna on chronically sun-damaged skin. The AAD guideline recognizes staged excision and appropriate Mohs approaches as options that provide comprehensive peripheral margin assessment while conserving tissue in selected settings. Treatment selection should account for location, lesion extent, and expertise. A clinical impression of a clear edge is not equivalent to microscopic clearance.
Apply it
An ill-defined lentigo maligna occupies a cosmetically sensitive facial site. Discuss a margin-controlled surgical approach that can address subclinical extension while preserving tissue, rather than relying only on the visible pigmentation to define clearance.
Common pitfall: In situ does not mean that observation is automatically appropriate. Margin-control techniques also should not be generalized to every invasive melanoma without considering guideline context.
48.Why can Mohs surgery be appropriate for a high-risk cutaneous SCC?
Mohs surgery removes tissue in stages while examining surgical margins microscopically, allowing further removal where tumor remains. This is valuable when recurrence risk, ill-defined growth, or a functionally important location makes reliable clearance and tissue preservation especially important. Recurrent cutaneous squamous cell carcinoma on the ear is a representative high-risk situation. Selection should consider the entire tumor and patient risk profile rather than assuming that every SCC requires the same operation or that surface diameter alone captures risk.
Apply it
A recurrent SCC on the ear has indistinct borders after prior treatment. Consider Mohs surgery because the combination of recurrence, site, and uncertain extent makes comprehensive margin assessment particularly useful for local management.
Common pitfall: A small measured diameter does not necessarily make an ear tumor low risk. Recurrence and anatomical site can change management even when the lesion looks limited.
49.What makes consent for a skin procedure informed and voluntary?
Explain the suspected diagnosis, the procedure’s purpose, expected benefits, material risks, and reasonable alternatives, including the consequences of deferring care. For a biopsy, distinguish obtaining a diagnosis from guaranteeing complete cancer treatment and discuss bleeding, infection, and scarring. Check understanding by asking the patient to explain the plan in their own words. A patient with decision-making capacity may decline; explore concerns without coercion, explain the risk of delayed diagnosis, and document the discussion, decision, and follow-up plan.
Apply it
A patient declines biopsy of a changing pigmented lesion because of scar concerns. Explain the diagnostic uncertainty and potential harm of delay, discuss feasible biopsy options, check understanding, and agree on documented follow-up while respecting the decision.
Common pitfall: A signed form alone does not demonstrate understanding or voluntariness. Do not promise a scar-free result or imply that diagnostic biopsy necessarily completes treatment.
50.Why is plain petrolatum useful after a routine skin biopsy?
A clean, moist, covered biopsy wound supports healing and reduces crust formation. AAD aftercare guidance recommends gentle cleansing, plain petroleum jelly, and an appropriate covering as directed. Routine topical antibiotic ointment is usually unnecessary and can cause contact allergy. Instructions should also address hand hygiene and when to seek help. The goal is not to keep the wound completely dry or repeatedly disinfect it with irritating products, but to support uncomplicated healing while watching for meaningful changes.
Apply it
A patient asks whether to use an over-the-counter antibiotic ointment on a clean biopsy site. Recommend the clinician’s cleansing and dressing instructions with plain petrolatum, and explain which symptoms should prompt contact with the practice.
Common pitfall: More antiseptic is not always better wound care. Routine antibiotic ointment can introduce allergic dermatitis that may then be mistaken for a wound infection.
51.Which changes after skin biopsy suggest infection rather than ordinary healing?
A biopsy wound may have mild early tenderness or localized inflammation, but increasing pain, spreading redness, warmth, swelling, purulent drainage, or fever warrants assessment for infection. The trend is often more informative than a single photograph. Ask when symptoms began and whether they are worsening after initial improvement. Evaluation should also consider contact dermatitis from adhesives or topical products. Matching the morphology and trajectory prevents both delayed infection treatment and unnecessary antibiotics for a noninfectious reaction.
Apply it
A biopsy site becomes progressively more painful with expanding warmth and purulent drainage several days after the procedure. Arrange clinical assessment rather than reassuring the patient solely because a small amount of early redness can be normal.
Common pitfall: Do not label every red wound infected or every postoperative symptom normal. Worsening pain and purulence carry different implications from stable mild redness or an itchy adhesive-shaped eruption.
Dermatopathology15%
52.What does acantholysis reveal about an autoimmune blister?
Acantholysis means loss of adhesion between epidermal keratinocytes. In pemphigus, antibodies against adhesion-related proteins disrupt cell connections, producing an intraepidermal split rather than simply a nonspecific surface erosion. Histology therefore helps connect fragile blisters with the mechanism of disease. The finding must be interpreted with clinical distribution and immunologic testing because cell separation alone does not supply every element of the diagnosis. Written descriptions should identify which cells separate and where the split occurs.
Apply it
A patient with oral erosions has a biopsy describing separation between epidermal cells. Recognize an adhesion failure pattern compatible with pemphigus and correlate it with antibody studies rather than treating the report as evidence of infection alone.
Common pitfall: A blister is an anatomical result, not a complete diagnosis. The level and mechanism of separation matter more than the generic presence of a cleft.
Pemphigus · Pemphigus: Diagnosis, Treatment, and Steps to Take
53.How should tissue and antibody testing resolve a nondiagnostic pemphigus biopsy?
Obtain lesional tissue from a fresh blister edge for routine histology in formalin; pemphigus vulgaris typically shows suprabasal acantholysis. Obtain a separate specimen of intact perilesional skin, close to a recent lesion, for direct immunofluorescence. Send that specimen in suitable immunofluorescence transport medium, such as Michel’s medium, according to laboratory instructions, rather than formalin. Expected DIF findings are intercellular epidermal IgG and/or C3 in a reticular pattern. Serum desmoglein 1 and desmoglein 3 IgG ELISA provides complementary antibody evidence.
Apply it
An eroded oral lesion yields only nonspecific inflammation. Reassess sampling with the laboratory: obtain suitable lesional tissue for histology and separate intact perilesional tissue for DIF, and add serum desmoglein antibody testing.
Common pitfall: An ulcerated or eroded specimen may lose diagnostic structures. Putting the only DIF specimen in formalin can prevent the intended study; coordinate separate specimens and transport before biopsy.
Diagnosis-and-management-of-pemphigus.pdf · Pemphigus: Diagnosis, Treatment, and Steps to Take
54.What does a nonspecific dermatitis biopsy establish about contact allergy?
A report describing eczematous dermatitis identifies a reaction pattern but does not identify the responsible allergen or establish that the eruption is allergic rather than irritant or atopic. Reconcile the report with exposure distribution, timing, occupational products, and topical treatments. When delayed contact allergy remains plausible, patch testing with later readings addresses the causal question that the routine biopsy has not answered. Positive reactions then require confirmation of relevant current exposure before directing avoidance.
Apply it
A hairdresser’s hand biopsy is reported as eczematous dermatitis. Persistent work-related recurrence still warrants a detailed exposure history and selected patch testing; the biopsy neither identifies the workplace allergen nor excludes contact allergy.
Common pitfall: Do not convert a broad histologic reaction pattern into a specific exposure diagnosis. Conversely, nonspecific histology does not make a reproducible clinical exposure pattern irrelevant.
Patch testing can find what's causing your rash · APPLIED Examination Overview
55.Which microscopic findings support basal cell carcinoma?
Basal cell carcinoma commonly shows nests or cords of basaloid cells, peripheral nuclear palisading, and separation or clefting between tumor and surrounding stroma. The combination is more informative than any single feature. Correlate the architecture with a clinical lesion such as a pearly papule or persistent ulcer, while recognizing that different histologic variants alter the growth pattern. A pathology description should be read as an arrangement of cells and stroma rather than a list of isolated keywords.
Apply it
A biopsy from a pearly facial papule shows basaloid nests with peripheral palisading and stromal clefts. Integrate the clinical and microscopic pattern to favor basal cell carcinoma over a keratinizing squamous tumor.
Common pitfall: Basaloid appearance alone is not a complete diagnosis. Architecture and stromal relationships help distinguish basal cell carcinoma from other tumors containing small dark cells.
Ohio State University Atlas of Head and Neck Pathology: Basal Cell Carcinoma
56.Why does an infiltrative basal cell carcinoma pattern matter?
Basal cell carcinoma is not limited to a rounded nodular growth pattern. Thin irregular strands infiltrating a fibrous stroma indicate a pattern whose microscopic extent may be less obvious clinically. Recognizing architecture therefore contributes to treatment planning and interpretation of margin concerns. The diagnosis and the growth pattern answer related but different questions: one identifies the tumor, while the other helps explain how it extends through tissue. Correlate the sampled pattern with the clinical site and treatment history.
Apply it
A seemingly small scar-like facial lesion yields narrow infiltrating basaloid cords in fibrous stroma. Communicate the growth pattern when planning treatment rather than assuming that the visible surface boundary captures the full extent.
Common pitfall: A pathology report naming basal cell carcinoma should not be read as though every subtype behaves identically. Limited sampling can also underrepresent a mixed tumor’s architecture.
Ohio State University Atlas of Head and Neck Pathology: Basal Cell Carcinoma
57.When should a wheal-like eruption prompt biopsy and clinicopathologic reassessment?
Ordinary urticarial wheals are transient, usually resolving within 24 hours. Individual lesions that remain fixed, are painful, or leave bruising raise concern for an alternative such as urticarial vasculitis and can justify skin biopsy. Provide the pathologist with individual lesion duration, symptoms, residual change, and systemic findings so that the tissue is interpreted against the correct differential. A generic description of hives omits the clinical information that distinguishes an ordinary transient wheal from a potentially different inflammatory process.
Apply it
A patient’s photographed plaques remain in the same sites for two days and leave bruising. Reconsider ordinary urticaria and pursue directed evaluation, including biopsy when appropriate, rather than escalating antihistamines solely because the lesions look wheal-like.
Common pitfall: Long overall disease duration alone does not justify biopsy of otherwise typical transient wheals. The behavior of each lesion supplies the discriminating clue.
Hives: Diagnosis and treatment · APPLIED Examination Overview
58.What does Breslow thickness measure in invasive melanoma?
Breslow thickness is measured from the top of the epidermal granular layer to the deepest invasive melanoma cell. If the tumor is ulcerated, measurement begins at the ulcer base. Report thickness to the nearest 0.1 mm. This vertical measurement is distinct from surface diameter and is central to primary tumor classification and management. If invasive melanoma reaches a transected biopsy base, the measured thickness may be only a minimum because deeper tumor remains unsampled.
Apply it
A melanoma report gives a depth of at least 0.9 mm and notes invasive tumor at the deep biopsy edge. Recognize the minimum measurement and clarify further assessment before making decisions that assume the maximum thickness is known.
Common pitfall: A precise decimal does not overcome incomplete sampling. Overlying crust, surface diameter, and the base of a transected specimen cannot substitute for the correct measurement landmarks and deepest invasive cell.
Guidelines of care for the management of primary cutaneous melanoma · Melanoma Treatment (PDQ®) — Health Professional Version
59.How are T1a and T1b melanoma distinguished in AJCC eighth-edition criteria?
In the AJCC eighth-edition framework reproduced by NCI, T1a melanoma is less than 0.8 mm thick without ulceration. T1b includes tumors less than 0.8 mm with ulceration and tumors from 0.8 through 1.0 mm with or without ulceration. The boundary is therefore not simply whether thickness exceeds one millimeter. These are primary tumor categories, not a complete stage assignment; nodal and distant disease information are needed when determining the overall stage.
Apply it
A completely sampled melanoma measures 0.9 mm and has no ulceration. Classify the primary tumor as T1b under AJCC eighth-edition criteria, then keep that designation separate from conclusions about nodal status or overall stage.
Common pitfall: Nonulcerated does not automatically mean T1a. A tumor measuring 0.8 to 1.0 mm falls within T1b even when ulceration is absent.
60.When does ulceration change melanoma primary tumor subcategory?
Histologic ulceration contributes prognostic information, but its effect on the primary tumor category depends on thickness. Under AJCC eighth-edition criteria, a 1.5-mm melanoma is T2a without ulceration and T2b with ulceration. A 0.9-mm melanoma is T1b whether ulceration is absent or present, because the entire 0.8–1.0-mm interval belongs to T1b. For tumors less than 0.8 mm, ulceration changes T1a to T1b. Primary tumor category remains separate from overall stage, which also incorporates regional and distant disease.
Apply it
Compare two 1.5-mm melanomas differing only in histologic ulceration: their categories are T2a and T2b. Repeat the comparison at 0.9 mm: both are T1b.
Common pitfall: Do not assume ulceration always changes the subcategory within a thickness interval. Clinical bleeding or scratching also does not establish histologic ulceration.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Build a differential from morphology, distribution, lesion timing, symptoms, and exposure history before selecting a test.
- Distinguish immediately dangerous presentations, including SJS/TEN, painful visual symptoms, and treatment-associated infection, from conditions suitable for routine follow-up.
- Interpret syphilis test combinations, timing criteria, quantitative changes, and organ involvement before selecting a treatment approach.
- Match treatment to mechanism and risk: antibiotic stewardship, biologic class, pediatric distribution, lesion behavior, and structural disease all change decisions.
- Practise dermoscopic assessment, diagnostic biopsy adequacy, tumor risk assessment, definitive margins, and postoperative symptom trajectories.
- Select appropriate tissue sites and transport, and reconcile written pathology with exposure patterns, lesion behavior, and antibody studies.
- Explain benefits, material risks, alternatives, and consequences of deferral; check understanding and respect informed decisions.
- Use the complete official skills overview to extend beyond this selective guide, and practise clinical images and photomicrographs separately.
A practical preparation plan
1. Map preparation to the official scope
Review the APPLIED skills overview and use its referenced CORE guide for nonexhaustive knowledge examples. Map each skill to clinical cases and identify gaps beyond the selected conditions in this guide.
2. Explain decisions before naming diagnoses
For each concept, identify the decisive finding, the closest alternative, the test or action that follows, and the consequence of choosing incorrectly. Use the mini-cases to practise reasoning aloud.
3. Use the learning questions diagnostically
Complete the questions without references, then review every alternative. Classify errors as missed clinical cue, test-interpretation error, management mismatch, or insufficient pathological correlation rather than treating the total as a pass prediction.
4. Add visual interpretation practice
Study representative clinical photographs, dermoscopic images, and photomicrographs using reliable educational collections. Describe the visible findings before viewing the diagnosis, and connect each image to a differential and management decision.
5. Rehearse sustained mixed-domain work
Use sustained mixed-domain practice to maintain concentration while switching between diagnostic, therapeutic, procedural, and pathological decisions. Review reasoning errors after each session, identify recurring assumptions, and revisit the clinical cues that would have changed the decision.
6. Consolidate mechanisms and boundaries
Use the flashcards for spaced recall. For each correct response, add one boundary condition, such as a high-risk site, sampling limitation, class-specific medication risk, or symptom that changes urgency.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- American Board of Dermatology
- ABD Certification Pathway Info Center
- APPLIED Exam
- APPLIED Exam Content Overview
- APPLIED Examination Overview
- CORE Exam Study Guide
- ABD Certification Pathway CORE Exam Study Guide
- Psoriasis treatment: Biologics
- Acne clinical guideline
- Acne: Diagnosis and treatment
- Preventing Scabies
- Clinical Care of Scabies
- Syphilis — STI Treatment Guidelines
- Alopecia Areata
- Patch testing can find what's causing your rash
- Hidradenitis Suppurativa
- Psoriatic arthritis: Overview
- SJS / TEN
- Hives: Diagnosis and treatment
- Rosacea: Diagnosis, Treatment, and Steps to Take
- Clinical Practice Guideline for the Management of Infantile Hemangiomas
- Treatment of Ringworm
- Choosing wisely: Recommendations about treatments, tests, and procedures
- Eczema types: Atopic dermatitis diagnosis and treatment
- Melanoma Treatment (PDQ®) — Health Professional Version
- Melanoma clinical guideline
- Squamous cell carcinoma: From symptoms to treatments
- Skin biopsy: Dermatologist-recommended wound care
- Pemphigus
- Pemphigus: Diagnosis, Treatment, and Steps to Take
- Ohio State University Atlas of Head and Neck Pathology: Basal Cell Carcinoma
- HUMIRA (adalimumab) U.S. Prescribing Information
- Consensus Reached Regarding Routine Testing for Latent Tuberculosis Infection in Patients with Psoriasis by the National Psoriasis Foundation and the International Psoriasis Council
- Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors
- Erythema multiforme
- Rosacea
- Guidelines of care for the management of primary cutaneous melanoma
- Clinical Practice Guideline for the Management of Infantile Hemangiomas
- Hidradenitis Suppurativa (HS): Diagnosis, Treatment, and Steps to Take
- Key messages: Urticaria guidelines
- Rosacea Symptoms, Causes, & Risk Factors | NIAMS
- Diagnosis-and-management-of-pemphigus.pdf
- Chapter 6: Choosing effect measures and computing estimates of effect | Cochrane
- Chapter 15: Interpreting results and drawing conclusions | Cochrane
- 2.1.1.pdf
- Patient Rights | AMA Code of Medical Ethics
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.